Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research
May 5th, 2021
6.4K views
A method is described to create organoids using patient-derived xenografts (PDX) for in vitro screening, resulting in matched pairs of in vivo/in vitro models. PDX tumors were harvested/processed into small pieces mechanically or enzymatically, followed by the Clevers’ method to grow tumor organoids that were passaged, cryopreserved and characterized against the original PDX.
Overview
This protocol describes the creation of organoids from patient-derived xenografts (PDX) for in vitro screening, establishing matched in vivo/in vitro models. The process involves harvesting and processing PDX tumors to generate organoid lines that can be characterized against the original PDX.
Key Study Components
Area of Science
- Neuroscience
- Biology
- Oncology
Background
- Patient-derived xenografts (PDX) are valuable for cancer research.
- Organoids provide a relevant in vitro model for studying tumors.
- Matching in vivo and in vitro models enhances experimental accuracy.
- This method allows for the preservation and characterization of organoids.
Purpose of Study
- To establish a library of paired PDX and organoid lines.
- To facilitate in vitro screening of cancer therapies.
- To improve the understanding of tumor biology through matched models.
Methods Used
- Harvesting PDX tumors and processing them into small pieces.
- Using enzymatic digestion followed by mechanical pipetting.
- Filtering the homogenate and washing the filtrate.
- Centrifuging the processed tissue for organoid culture.
Main Results
- Successful generation of organoids from PDX tumors.
- Establishment of matched in vivo/in vitro models.
- Characterization of organoids against original PDX samples.
- Potential for in vitro screening of therapeutic agents.
Conclusions
- The method provides a reliable approach to create organoids from PDX.
- Matched models enhance the relevance of in vitro studies.
- This protocol can be adapted for various cancer types.
Frequently Asked Questions
What are patient-derived xenografts?
Patient-derived xenografts (PDX) are tumors taken from patients and implanted into immunocompromised mice for research purposes.
How are organoids created from PDX?
Organoids are created by harvesting PDX tumors, processing the tissue, and culturing it using specific methods.
What is the significance of matched in vivo/in vitro models?
Matched models allow researchers to compare the behavior of tumors in vivo and in vitro, improving the relevance of experimental results.
Can this method be used for different types of cancer?
Yes, the protocol can be adapted for various cancer types to create organoids from PDX.
What are the advantages of using organoids for screening?
Organoids provide a more accurate representation of patient tumors, allowing for better screening of potential therapies.
Executive Industry Relevance
Establishing matched in vivo/in vitro patient-derived xenograft (PDX) and PDX-derived organoid (PDXO) pairs addresses the need for translationally relevant, scalable cancer models in drug discovery. This dual-model system enables high-throughput in vitro screening while preserving the predictive fidelity of in vivo PDX models, supporting more confident portfolio triage and mechanistic de-risking at early discovery inflection points. The approach enhances translational continuity and reduces attrition risk by aligning preclinical pharmacology with patient tumor heterogeneity.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of therapeutic hypotheses in models reflecting patient tumor diversity.
- Supports functional target validation by comparing drug responses across matched in vivo and in vitro systems.
- Facilitates mechanistic de-risking through genomic and phenotypic concordance analysis.
- Improves predictive confidence for advancing candidates into preclinical development.
Screening & Assay Development
- Provides a scalable platform for high-throughput compound screening using PDXO in 384-well formats.
- Enables assay standardization and reproducibility by leveraging genetically matched model pairs.
- Delivers quantitative viability and drug sensitivity readouts for robust compound evaluation.
- Supports screening readiness and platform reuse across diverse tumor types.
Translational & Preclinical Research
- Aligns in vitro and in vivo pharmacology data to improve translational biomarker identification.
- Maintains disease relevance by preserving genomic and histopathological features of patient tumors.
- Enables risk-adjusted advancement decisions based on concordant drug response profiles.
- Strengthens continuity from discovery through preclinical validation by using matched model systems.
Pipeline & Workflow Integration
This method integrates from early discovery through lead identification and preclinical validation, bridging in vitro screening with in vivo efficacy studies using genetically matched models.
- Discovery Biology: Supports hypothesis testing and pathway clarification in patient-relevant systems.
- Screening: Delivers reproducible, quantitative drug response data in high-throughput organoid assays.
- Analytics: Enables direct comparison of genomic, transcriptomic, and pharmacological outputs between PDX and PDXO.
- Translational Research: Facilitates biomarker alignment and translational continuity by preserving tumor heterogeneity.
- Enterprise Reuse: Establishes a reusable library of matched model pairs for ongoing portfolio evaluation.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in candidate selection.
- Operational Value: Standardizes workflows and enables scalable, reproducible pharmacology studies.
- Strategic Value: Improves go/no-go decision quality and capital efficiency by aligning models with clinical heterogeneity.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of drug candidates.
Implementation Considerations
- Requires expertise in tissue processing, organoid culture, and PDX handling.
- Demands access to specialized instrumentation for cell dissociation, imaging, and high-throughput screening.
- Necessitates cross-team standardization of protocols for reproducibility and data comparability.
- May require adaptation for different tumor types or model systems based on tissue characteristics.
- Throughput and scalability are limited by initial PDX availability and organoid culture success rates.
Biopharma FAQs
Why does null hypothesis testing matter for PDXO drug sensitivity assays?
Null hypothesis testing in PDXO drug sensitivity assays enables objective evaluation of compound effects by comparing treated and control groups, supporting robust target validation. This statistical rigor ensures that observed differences in viability or response are not due to random variation, increasing confidence in early discovery decisions. Reliable hypothesis testing underpins mechanistic de-risking and portfolio triage.
How does independent variable isolation in PDXO screening fit the discovery pipeline?
Isolating independent variables, such as drug concentration or genetic background, in PDXO screening allows precise attribution of observed effects to specific interventions. This clarity is essential for mechanistic studies and supports the transition from in vitro findings to in vivo validation within the discovery pipeline. It streamlines candidate prioritization by reducing confounding factors.
What do quantitative viability measurements in 384-well PDXO assays enable?
Quantitative viability measurements in 384-well PDXO assays provide high-resolution data on drug response, enabling direct comparison of compound efficacy across multiple conditions. These outputs support data-driven go/no-go decisions and facilitate reproducible, scalable screening workflows. Quantitative readouts also enhance cross-study comparability and downstream analytics.
Why are replication requirements critical for cross-functional PDX/PDXO studies?
Replication in PDX/PDXO studies ensures that observed drug responses and genomic concordance are consistent and reproducible across experiments and teams. This reliability is vital for cross-functional collaboration, enabling integration of data from discovery, screening, and translational research. Replication strengthens the evidence base for advancing candidates through the pipeline.
What statistical analysis capabilities are required before implementing PDXO pharmacology workflows?
Implementing PDXO pharmacology workflows requires statistical capabilities for analyzing viability, drug sensitivity, and genomic concordance data. Teams must be able to perform hypothesis testing, calculate correlation coefficients, and assess reproducibility to ensure robust interpretation of results. These analyses underpin confident decision-making and risk-adjusted advancement in biopharma R&D.
